UNSPSC 51431603: Devapamil

This classification denotes a calcium channel blocker with the molecular formula C26H36N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M6142PTV7J, chemically known as 2-(3,4-dimethoxyphenyl)-2-isopropyl-5-((m-methoxyphenethyl)methylamino)valeronitrile but generally known as devapamil, which bears US NIH Compound Identifier 65832. European Medicines Agency schedules Devapamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07015MIG.

UNSPSC 51431603 Devapamil is a Commodity code representing individual pharmaceutical products procured by state and local healthcare and emergency services agencies. State and local governments use this code to source specific medications for fire rescue services, state health and human services programs, and multistate cooperative purchasing alliances that distribute pharmaceuticals across participating government facilities. The work involves supplying branded or generic pharmaceutical products with specified National Drug Codes, maintaining strict expiration and shelf-life requirements, securing supply chain compliance certifications (cGMP, DSCSA), arranging delivery within contractually mandated timeframes, and managing product replacement and pickup of expired inventory. Issuing bodies include municipal fire departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). Recent solicitations reflect a mix of direct municipal procurement and coordinated multistate purchasing vehicles.

Recent activity spans Florida, Texas, and the MMCAP region (Minnesota and Oregon). The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with delivery within ten calendar days and a one-year contract term at an estimated value of $40,000.00; bids closed April 8, 2026, with a 5 percent bid discount available to Small Local Business Enterprises (SLBEs). The Texas Health and Human Services Commission posted an RFI in April 2026 (HHS0017013) seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, administering the MMCAP cooperative purchasing vehicle, issued an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; the RFP weighted price competitiveness at 75 percent and required manufacturers to maintain relationships with at least two authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, or Morris & Dickson).